GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

Discover a study that offers new insight into the link between frailty and steatotic liver disease in older adults.

The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.